Extended Data Table 3 Cost-effectiveness analyses of the ctDNA-guided RAT strategy versus the conventional fixed-course, static treatment approach

From: Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma

  1. Abbreviations: ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life years; CCRT, concurrent chemoradiotherapy; GP, gemcitabine plus cisplatin; RAT, risk-adaptive treatment.
Back to article page